Fundz

Who to call at Innovent Biologics, and when

Fundz watches for the moments Innovent Biologics starts buying, and tells you who to reach.

  • An alert the day Innovent Biologics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Innovent Biologics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Innovent Biologics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Innovent Biologics partners with Pfizer to develop oncology medicines worth up to $10.5 billion.

May 29, 2026

Contract Type

partnership

SuzhouManufacturingBiotechnologyHealth CarePharmaceuticalPharmaceutical Manufacturing

Description

Innovent Biologics entered a partnership with Pfizer to develop 12 early-stage oncology medicines, involving licensing and co-commercialization. The deal includes an upfront payment of $650 million and potential milestone payments of up to $9.85 billion.

Company Information

Company

Innovent Biologics

Location

Suzhou, Jiangsu, China

About

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically.

Related People

Fei
Likely contact at this company
••••••••@••••••••

See Fei's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Innovent Biologics's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Innovent Biologics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.